Woodford bails on Sanofi while betting on biotech; GSK dishes on new U.S. R&D hub;

@FierceBiotech: Turns out drugmakers don't tell the whole truth about FDA rejections. More | Follow @FierceBiotech

@JohnCFierce: This will be a biotech to watch: Unum hits the gas on next-gen CAR-T tech after banking $65M round. Story | Follow @JohnCFierce

@DamianFierce: Listen to two arguably well-informed people talk about the week in biopharma. FierceBiotech Radio | Follow @DamianFierce

> U.K. biopharma investor Neil Woodford has dumped his stake in Sanofi ($SNY) and redoubled his bets on emerging biotech companies around Europe. News

> GlaxoSmithKline ($GSK), in the process of consolidating much of its U.S. R&D division, offered a glimpse at a planned research hub in Pennsylvania. Story

> Alnylam's ($ALNY) RNAi treatment for autoimmune disorders successfully silenced its target by as much as 96% in a study on 12 healthy volunteers. The company plans to move the candidate into a trial on the rare paroxysmal nocturnal hemoglobinuria by the end of the year. More

Medical Device News

@FierceMedDev: Illumina teams up with Chinese genomics firm for noninvasive prenatal test development. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Boston Scientific touts improved spinal cord stimulator at neuromodulation conference. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: FDA slaps Insulet with warning letter over insulin pumps. Article | Follow @EmilyWFierce

> Boston Scientific touts improved spinal cord stimulator at neuromodulation conference. Story

> Philips cautions on cardio mortality after ResMed sleep apnea data, intros cardiac imaging tool. Article

Pharma News

@FiercePharma: AB Science struggles to break out as canine cancer drug flounders. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Mylan recalls more injected cancer drugs it made for #Pfizer at its Agila plants in India. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Big Data study flags 'fairly compelling' link between stomach blockbusters and heart risks. Report | Follow @CarlyHFierce

> GSK deal keeps paying off for Novartis with more positive Arzerra data. Story

> Prisoners accuse Massachusetts of barring them from pricey hep C meds. Article

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.